Chimerix Announces Closing Of TEMBEXA Sale To Emergent BioSolutions; $238M In Upfront Payment Received At Closing With Additional $136.5M In Potential Milestone Payments Plus Royalties
DURHAM, N.C., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Chimerix, Inc. (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing